Glaukos Corporation (GKOS)
NYSE: GKOS
· Real-Time Price · USD
90.66
2.42 (2.74%)
At close: May 08, 2025, 3:59 PM
90.12
-0.60%
Pre-market: May 09, 2025, 06:02 AM EDT
Glaukos Revenue Breakdown
| Period Ending | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
|---|---|---|---|---|
| Corneal Health Revenue | 14.88M | 12.9M | 6.61M | 11.2M |
| Corneal Health Revenue Growth | +15.29% | +95.23% | -41.00% | n/a |
| Glaucoma Revenue | 58.36M | 51.93M | 24.95M | 44.13M |
| Glaucoma Revenue Growth | +12.38% | +108.14% | -43.47% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|
| International Revenue | 95.31M | 144.66M | 170.8M |
| International Revenue Growth | -34.11% | -15.30% | n/a |
| United States Revenue | 219.4M | n/a | n/a |
| United States Revenue Growth | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 64M | 66.19M | 61.98M | 63.03M | 54.25M | 53.14M | 53.65M | 51.93M | 47.15M | 49.9M | 43.95M | 47.57M | 44.47M | 45.3M | 41.92M | 43.79M | 38.95M | 38.12M | 50.55M | 59.61M | 44.44M | 37.66M | 34.92M | 32.1M | 31.63M | 28.64M | 27.16M | 25.96M | 24.14M | 24.68M | 21.48M | 20.49M | 16.85M | 15.12M | 12.29M | 12.39M | 11.24M | 12.52M | 7.82M |
| Selling, General, and Administrative Revenue Growth | -3.31% | +6.80% | -1.68% | +16.20% | +2.09% | -0.96% | +3.32% | +10.13% | -5.51% | +13.54% | -7.60% | +6.96% | -1.83% | +8.06% | -4.27% | +12.44% | +2.18% | -24.59% | -15.21% | +34.13% | +18.02% | +7.82% | +8.79% | +1.49% | +10.45% | +5.46% | +4.59% | +7.55% | -2.16% | +14.87% | +4.82% | +21.60% | +11.47% | +23.05% | -0.84% | +10.28% | -10.22% | +60.13% | n/a |
| Research and Development Revenue | 34.75M | 34.43M | 30.73M | 39.06M | 33.3M | 36.23M | 35.17M | 35.81M | 28.87M | 41.71M | 26.88M | 26.68M | 33.85M | 29.26M | 21.22M | 21.24M | 20.3M | 18.97M | 24.87M | 20.03M | 18.78M | 19.31M | 13.93M | 12.96M | 13.2M | 12.61M | 10.91M | 10.53M | 9.8M | 14.95M | 8.94M | 7.4M | 7.81M | 6.96M | 7.06M | 6.29M | 6.17M | 7.34M | 5.24M |
| Research and Development Revenue Growth | +0.93% | +12.04% | -21.34% | +17.30% | -8.09% | +3.02% | -1.79% | +24.05% | -30.79% | +55.20% | +0.75% | -21.18% | +15.69% | +37.88% | -0.12% | +4.63% | +7.03% | -23.73% | +24.17% | +6.67% | -2.78% | +38.65% | +7.51% | -1.86% | +4.69% | +15.63% | +3.62% | +7.34% | -34.43% | +67.22% | +20.85% | -5.23% | +12.25% | -1.52% | +12.18% | +1.98% | -15.89% | +40.06% | n/a |